Elucidating the effects of patient weight and metabolic state on circulating nanoparticle efficacy
Elucidating the effects of patient weight and metabolic state on circulating nanoparticle efficacy
批准号:
8957960
负责人:
Paul Dalhaimer
金额:
$34.26万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-17 至 2019-08-31
关键词:
Adipose tissueAffectAffinityAnimalsAntineoplastic AgentsAreaArterial Fatty StreakArteriesArteriosclerosisAtherosclerosisAttentionBehaviorBindingBiodistributionBiological AssayBiomedical EngineeringBlood CirculationCancer ModelCancer PatientCell FractionChargeChemistryClinicDataDependenceDietDimensionsDiseaseDrug Delivery SystemsDyesEffectivenessFatty LiverFatty acid glycerol estersFutureGeometryGoalsHepatic MassHepatomegalyHumanImageIn VitroIndividualInflammationLibrariesLifeLipidsLipoprotein ReceptorLipoproteinsLiverLow-Density LipoproteinsMalignant NeoplasmsMeasuresMetabolicMetabolic DiseasesMetabolismMethodologyModelingMusMutationObese MiceObesityOncogenesOrganOverweightPatientsPharmaceutical PreparationsPhysiologicalPlasmaPlayPropertyRodentRoleScientistSpleenTechnologyTestingTrustUnited States National Institutes of HealthWeightWorkbasecancer therapychemotherapydesignefficacy testingimprovedin vivoinsightinterestmacrophagemouse modelnanoparticlenanoscalenovelparticlepersonalized medicinepublic health relevanceresearch studysuccesstumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: Nanoparticles carrying dyes and drugs that can be targeted to a wide variety of cancers have shown great promise in the treatment of this disease. However, most if not all of the mouse models that test the effectiveness of nanoparticles in eradicating cancers take place in lean, young mice whereas the vast majority of humans that will develop cancers and thus potentially be treated with nanoparticle technologies will be obese and have additional metabolic imbalances. We hypothesize that the metabolic condition of cancer patients will play a crucial role in the effectiveness of chemotherapies that are delivered via nanoparticles. In fact, we have compelling preliminary data showing that excessive white adipose tissue (WAT) is a major sink for nanoparticles in obese mice. We have created a unique nanoparticle library that spans both the geometries and chemistries of previously successful nanoparticles that we propose to administer to prescient mouse models of human metabolic conditions with a main focus on 1) excessive WAT, 2) fatty/enlarged livers, 3) varying lipoprotein levels, 4) atherosclerosis, and 5) the first-ever combinations of metabolic conditions and oncogene mutations. The dynamic biodistribution of the nanoparticles - the main assay for future efficacy in treating cancers - wil be assessed using cutting edge organ imaging. Results generated from in vivo experiments will be confirmed in reductionist in vitro experiments for the purpose of fleshing out nanoparticle localization mechanisms at the cellular level. The overall approach differs from the standard model of synthesis of a single nanoparticle and administration to lean rodents, which tends to provide nanoparticle-specific insights in idealized physiological settings. Instead, the proposed fundamental methodologies eliminate dependence upon the success of a single nanoparticle and provide a general and novel gateway toward complete understanding of nanoparticle-patient interactions that will be elucidated in enough detail as to drastically improve nanoparticl efficacy for a plethora of targeting applications with a special focus on cancer.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.jconrel.2021.07.045
发表时间:
2021-08-06
期刊:
JOURNAL OF CONTROLLED RELEASE
影响因子:
10.8
作者:
[Raith,Mitch, Kauffman,Sarah J., Dalhaimer,Paul]
通讯作者:
Dalhaimer,Paul
Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles.
肥胖和炎症影响基于 PEG 的纳米颗粒的药代动力学特征。
DOI:
10.1016/j.jconrel.2023.02.007
发表时间:
2023
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Raith,Mitch, Nguyen,Nicole, Kauffman,SarahJ, Kang,Namgoo, Mays,Jimmy, Dalhaimer,Paul]
通讯作者:
Dalhaimer,Paul
Characterization of constitutively active Arp2/3
-
批准号:7229011
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2005
-
负责人:Paul Dalhaimer
-
依托单位:
Characterization of constitutively active Arp2/3
-
批准号:7060769
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2005
-
负责人:Paul Dalhaimer
-
依托单位:
Characterization of constitutively active Arp2/3
-
批准号:6937329
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2005
-
负责人:Paul Dalhaimer
-
依托单位:
海外基金